| Identification | More | [Name]
9-Oxo-10(9H)-acridineacetic acid | [CAS]
38609-97-1 | [Synonyms]
10-carboxymethyl-9-acridanone
9-oxo-10(9h)-acridineaceticaci
9-oxo-10(9h)-acridineaceticacid
(9 10-DIHYDRO-9-OXO-10-ACRIDINYL)ACETIC
acridin-9(10H)-one-n-acetic acid
ACRIDONE ACETIC ACID
(9-Oxo-10(9H)-acridinyl)acetic acid
10-Carboxymethylacridin-9(10H)-one
(9,10-Dihydro-9-oxo-10-acridinyl)acetic acid, 10-(Carboxymethyl)-9(10H)acridone
9-Oxo-9,10-dihydro-10-acridineacetic acid | [EINECS(EC#)]
634-833-1 | [Molecular Formula]
C15H11NO3 | [MDL Number]
MFCD00157050 | [Molecular Weight]
253.25 | [MOL File]
38609-97-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
~289 °C (dec.)
| [Boiling point ]
486.6±34.0 °C(Predicted) | [density ]
1.362 | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Aqueous Base (Slightly), DMSO (Slightly) | [form ]
Solid | [pka]
3.69±0.10(Predicted) | [color ]
Pale Yellow to Light Yellow | [λmax]
410nm(H2O)(lit.) | [BRN ]
227508 | [InChI]
InChI=1S/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18) | [InChIKey]
UOMKBIIXHQIERR-UHFFFAOYSA-N | [SMILES]
C1=C2C(N(CC(O)=O)C3=C(C2=O)C=CC=C3)=CC=C1 | [CAS DataBase Reference]
38609-97-1(CAS DataBase Reference) |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS07 | [Signal word ]
Warning | [Hazard statements ]
H315-H319-H335 | [Precautionary statements ]
P261-P305+P351+P338 | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [RTECS ]
AR7190000
| [HS Code ]
2933.99.8290 |
| Hazard Information | Back Directory | [Description]
9-Oxo-10(9H)-acridineacetic acid , also known as Cridanimod or XBIO-101, is a small molecule that can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Cridanimod is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone (LH) release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen release from the ovaries. This leads to an inhibition of cellular growth in estrogen-dependent tumor cells.
| [Uses]
9-Oxo-10(9H)-acridineacetic acid is a reagent for pre-column derivatization of amino acids for fluorescent determination in HPLC and it is also a building block in pharmaceutics. | [Definition]
ChEBI:Cridanimod is a member of acridines. It is functionally related to an acridone. | [Synthesis]
The synthetic method consisted of the following steps: 29.2 g of [Pmim]OH ionic liquid was added to a three-necked flask equipped with a condensation reflux device, followed by the addition of 19.5 g of acridinone and 11.3 g of chloroacetic acid, which was homogenized by stirring at room temperature. The reaction mixture was allowed to stand at room temperature and then reacted under stirring conditions for 12 hours. After completion of the reaction, the residue was washed with 25 mL of methanol and dried to give 24.2 g of 2-(9-oxoacridin-10(9H)-yl)acetic acid in 95.7% yield. | [storage]
Store at -20°C | [References]
[1] Patent: CN104592115, 2017, B. Location in patent: Paragraph 0016; 0017; 0018
[2] Patent: CN108456166, 2018, A. Location in patent: Paragraph 0030; 0044; 0045; 0047; 0050; 0051; 0072
[3] Acta Poloniae Pharmaceutica - Drug Research, 2010, vol. 67, # 2, p. 211 - 214 |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
|